Chronic inflammation is a key driver of cardiomyopathy in older adults, highlighting the potential of anti-inflammatory interventions to slow disease progression and improve clinical outcomes.
Highlights the conceptual role of chronic inflammation as a driver of cardiomyopathy in older adults and the potential for anti-inflammatory interventions to slow disease progression.
Cardiomyopathy is a disorder of the myocardium characterized by structural and functional abnormalities that result in impaired cardiac mechanical and/or electrical function. Aging induces a natural, gradual decline in cardiac structure and function (cardiac aging) that increases susceptibility to cardiomyopathy and exacerbates pre-existing cardiomyopathy. Despite ongoing research, the complex, multifactorial nature of this process substantially increases the risk of heart failure and remains a significant clinical and scientific challenge. With rising global life expectancy, effective pharmacological strategies are urgently needed. Here, we discuss chronic inflammation as a key driver of cardiomyopathy in older adults and explore perspectives on anti-inflammatory interventions that may slow disease progression and improve outcomes for the older population.
Qiu et al. (Sun,) conducted a review in Cardiomyopathy and heart failure in older adults. Anti-inflammatory interventions was evaluated. Chronic inflammation is a key driver of cardiomyopathy in older adults, highlighting the potential of anti-inflammatory interventions to slow disease progression and improve clinical outcomes.